Jubilant Organosys Ltd, headquartered in Noida, announced today that its subsidiaries Jubilant Biosys Ltd (Bangalore based) and Jubilant Chemsys Ltd (Noida based) have entered into three way drug discovery partnership with Orion, a leading pharmaceutical company of Finland. Under this “Hybrid & Integrated” arrangement, Orion will have the option of utilizing resources flexibly from both Jubilant Biosys Ltd and Jubilant Chemsys Ltd based on the requirements of its drug discovery projects.

Commenting on the development, Sri Mosur, CEO & President, Jubilant Biosys,  said, "We are very pleased to partner with Orion and offer our integrated Discovery services enabling the discovery efforts at Orion.  Jubilant's Flexible and Hybrid platform of innovative discovery chemistry, biology and insilico services demonstrates its ability to customize and accelerate global drug discovery efforts. It will be our continued endeavor to enable creative partnering models supporting our scientific capabilities.”

This arrangement bears testimony to the expertise of Jubilant Biosys and Chemsys scientists. A strong team comprising Biologists and Chemists will be engaged in carrying out research on Orion’s projects at the two subsidiaries as per the need of the projects.

Expressing their pleasure with the partnership, Dr Antti Haapalinna, Vice President, Research, R&D of Orion Corporation said," We are happy to partner with Jubilant and are confident of scaling up our drug discovery programs with support from their scientific team.  Through this partnership, we would achieve a good basis for success as it would complement our in-house discovery effort."

Notes to the Editors

About Jubilant Biosys

Jubilant Biosys Ltd. (www.jubilantbiosys.com) is a subsidiary of Jubilant Organosys Ltd., which provides integrated drug discovery and development solutions to the global pharmaceutical industry. The 120,000 sq. ft. state of the art Jubilant Biosys Center in Bangalore integrates the capabilities of over 300 scientists specializing in multiple disciplines including biology, chemistry, structural biology, pharmacology, molecular modelling, crystallography and information technology to support collaborations with global pharma companies in USA, Europe and Japan.

 About Jubilant Chemsys

Jubilant Chemsys Ltd. is a subsidiary of Jubilant Organosys Ltd., which provides medicinal chemistry and synthetic chemistry services to the global pharmaceutical industry. The 85,000 sq. ft. state of the art facilities’ based out of Noida has over 300 scientists specializing in chemistry across various chemical classes and is associated with over 40 customers across the globe. 

About Jubilant Organosys

Jubilant Organosys Ltd. is an integrated pharmaceutical industry player, one of the largest custom research and manufacturing services (CRAMS) and drug discovery and development services companies out of India. The company has a presence across the pharmaceutical value chain for products and services such as proprietary products ,exclusive synthesis, active pharmaceutical ingredients, contract manufacturing of sterile injectables (liquids and lyophilized) products, non-steriles (ointments, creams and liquid) and radiopharmaceuticals, drug discovery services, medicinal chemistry services, clinical research services ,generic dosage forms and Health Care. Jubilant Organosys has geographically diversified manufacturing facilities at ten locations worldwide. Together, these help Jubilant cater to 150 customers across more than 50 countries around the world. For more information, please visit www.jubl.com

 About Orion

 Orion Corporation is a Finnish listed company, which develops, manufactures and markets pharmaceuticals, active pharmaceutical ingredients and diagnostic tests for global markets. Orion has been building well-being for over 90 years. Pharmaceuticals account for about 95% of Orion’s net sales, of which a considerable part comes from proprietary patented pharmaceutical innovations. Orion carries on intensive research with the aim of introducing new innovative treatments to global markets. The core therapy areas in Orion’s product and research strategy are central nervous system, oncology and critical care, respiratory medicines administered with the Easyhaler device.  

In global marketing, Orion collaborates through in licensing partnerships with other pharmaceutical companies. Stalevo® and Comtess®/Comtan®, for Parkinson’s Disease, are the largest products by sales in Orion’s portfolio. These products are marketed in collaboration with Novartis, and they are the most significant globally marketed products for Orion.

 Orion also has a large portfolio of generic, off-patent prescription medicines, hospital treatments and self-care products. These products are sold mainly in Finland, other Nordic countries, the new EU countries and Germany.  

For more information, please visit www.orion.fi/english

---ENDS---

For more information on release, contact:

India
For Media	For Investors
Seema Ahuja	Deepak Malik
VP- Corporate Marketing & Communication	Manager - Investor Relations
Jubilant Organosys Limited	Jubilant Organosys Limited
1-A, Sector 16-A, Institutional Area	1-A, Sector 16-A, Institutional Area
Noida - 201301 (UP)	Noida - 201301 (UP)
Ph: +91-120-4361062	Ph: +91-120-4361114
Mobile - +91-9810631779	Fax: (0120) 2516629
Email: seema_ahuja@jubl.com	E-mail: deepak_malik@jubl.com

PR Agency	IR Agency
Imprimis Life PR	Citigate Dewe Rogerson
Priyanka Bhattacharji	Siddharth Rangnekar
+91 9811698914	Tel: +91 -22 4007 5005
email:pbhattacharji@imprimispr.com	Fax: +91-22- 2284 4561
	E-mail: siddharth@cdr-india.com
For Business Queries
Saurabh Kapure
Senior Manager Business Development
Jubilant Biosys and Jubilant Chemsys Ltd.
Direct: +91-80-6662 8852
Fax:+91-80-66628333
e-mail: saurabh_rk@jubilantbiosys.com

Disclaimer: Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Organosys may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Back